SK282832B6 - Použitie reakčného produktu alkaloidov Chelidonium maijus L. s triaziridídom tiofosforečnej kyseliny - Google Patents

Použitie reakčného produktu alkaloidov Chelidonium maijus L. s triaziridídom tiofosforečnej kyseliny Download PDF

Info

Publication number: SK282832B6
Authority: SK; Slovakia
Prior art keywords: maijus; chelidonium; alkaloids; reaction product; tiophosphoric
Prior art date: 1995-06-01

Application number

SK1625-97A

Other languages

English (en)

Slovak (sk)

Other versions

SK162597A3 (en

Inventor

Wassyl Nowicky

Original Assignee

Wassyl Nowicky

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-06-01

Filing date

1996-05-30

Publication date

2002-12-03

1996-05-30 Application filed by Wassyl Nowicky filed Critical Wassyl Nowicky

1998-05-06 Publication of SK162597A3 publication Critical patent/SK162597A3/sk

2002-12-03 Publication of SK282832B6 publication Critical patent/SK282832B6/sk

Links

229930013930 alkaloid Natural products 0.000 title claims abstract description 8
239000007795 chemical reaction product Substances 0.000 title claims abstract description 6
241001017738 Chelidonium <beetle> Species 0.000 title claims abstract description 5
239000002253 acid Substances 0.000 title claims abstract description 4
QNNALNZLUPVUBO-UHFFFAOYSA-N triaziridine Chemical compound N1NN1 QNNALNZLUPVUBO-UHFFFAOYSA-N 0.000 title abstract 2
239000003814 drug Substances 0.000 claims abstract description 7
238000011282 treatment Methods 0.000 claims abstract description 7
150000003839 salts Chemical class 0.000 claims abstract description 5
230000005855 radiation Effects 0.000 claims description 5
238000004519 manufacturing process Methods 0.000 claims description 4
238000011321 prophylaxis Methods 0.000 claims description 4
210000001685 thyroid gland Anatomy 0.000 claims description 4
150000007513 acids Chemical class 0.000 claims description 2
201000005485 Toxoplasmosis Diseases 0.000 claims 2
238000004062 sedimentation Methods 0.000 claims 2
PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 claims 1
230000003110 anti-inflammatory effect Effects 0.000 claims 1
239000000427 antigen Substances 0.000 claims 1
102000036639 antigens Human genes 0.000 claims 1
108091007433 antigens Proteins 0.000 claims 1
238000004820 blood count Methods 0.000 claims 1
230000003247 decreasing effect Effects 0.000 claims 1
230000003111 delayed effect Effects 0.000 claims 1
230000006866 deterioration Effects 0.000 claims 1
235000012054 meals Nutrition 0.000 claims 1
235000016709 nutrition Nutrition 0.000 claims 1
230000035764 nutrition Effects 0.000 claims 1
210000002966 serum Anatomy 0.000 claims 1
238000012360 testing method Methods 0.000 claims 1
238000002560 therapeutic procedure Methods 0.000 claims 1
230000004584 weight gain Effects 0.000 claims 1
235000019786 weight gain Nutrition 0.000 claims 1
208000019155 Radiation injury Diseases 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
-1 alkaloid phosphorus derivatives Chemical class 0.000 description 3
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
150000003017 phosphorus Chemical class 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
241000224466 Giardia Species 0.000 description 1
RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical compound OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000012752 auxiliary agent Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
239000000824 cytostatic agent Substances 0.000 description 1
230000001085 cytostatic effect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000003831 deregulation Effects 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000005755 formation reaction Methods 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
230000036244 malformation Effects 0.000 description 1
238000000034 method Methods 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
239000000243 solution Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
150000003579 thiophosphoric acid derivatives Chemical class 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/664—Amides of phosphorus acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Toxicology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines Containing Plant Substances (AREA)

SK1625-97A 1995-06-01 1996-05-30 Použitie reakčného produktu alkaloidov Chelidonium maijus L. s triaziridídom tiofosforečnej kyseliny SK282832B6 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
AT0093695A AT407833B (de)	1995-06-01	1995-06-01	Mittel zur behandlung von strahlenschäden
PCT/AT1996/000099 WO1996038154A1 (de)	1995-06-01	1996-05-30	Mittel zur behandlung von strahlenschäden

Publications (2)

Publication Number	Publication Date
SK162597A3 SK162597A3 (en)	1998-05-06
SK282832B6 true SK282832B6 (sk)	2002-12-03

Family

ID=3503254

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1625-97A SK282832B6 (sk)	1995-06-01	1996-05-30	Použitie reakčného produktu alkaloidov Chelidonium maijus L. s triaziridídom tiofosforečnej kyseliny

Country Status (15)

Country	Link
US (1)	US5981512A (de)
EP (1)	EP0831841A1 (de)
JP (1)	JPH11505851A (de)
KR (1)	KR19990022036A (de)
CN (1)	CN1167423C (de)
AT (1)	AT407833B (de)
AU (1)	AU713853B2 (de)
CA (1)	CA2222539A1 (de)
CZ (1)	CZ290489B6 (de)
DE (1)	DE19680394D2 (de)
NZ (1)	NZ308024A (de)
SK (1)	SK282832B6 (de)
UA (1)	UA42842C2 (de)
WO (1)	WO1996038154A1 (de)
ZA (1)	ZA964387B (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH695417A5 (de) *	2001-11-15	2006-05-15	Ddr Wassyl Nowicky Dipl Ing	Verfahren zur Umsetzung von Alkaloiden.
EP1459753A1 (de)	2003-03-18	2004-09-22	Nowicky, Wassyl, Dipl.-Ing. DDr.	Quaternäre Chelidonin- und Alkaloidderivate, Verfahren zu deren Herstellung und deren Verwendung in der Herstellung von Arzneimitteln
EP1833839A1 (de) *	2004-09-20	2007-09-19	Wassyl Nowicky	Quaternäre alkaloidderivate von chelidonium majus l
CN104487066B (zh)	2012-07-23	2020-06-09	国立大学法人东京大学	放射线损害的预防和/或治疗剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AT354644B (de) *	1975-12-19	1980-01-25	Nowicky Wassili	Verfahren zur herstellung von neuen salzen von alkaloidderivaten von thiophosphorsaeure
AT377988B (de) *	1976-06-28	1985-05-28	Nowicky Wassili	Verfahren zur herstellung von neuen phosphorderivaten von alkaloiden
DE3128018A1 (de) *	1981-07-13	1983-04-07	Wassyl 1060 Wien Nowicky	"verfahren zum diagnostizieren und fuer die therapeutische behandlung von tumoren und/oder infektioesen krankheiten verschiedenster art unter praeparativem einsatz von alkaloid-verbindungen bzw. deren salze"
US4970212A (en) *	1982-05-18	1990-11-13	Nowicky Wassili	Method of treating human illnesses which compromise the ability to mount an effective immunological response
US4735945A (en) *	1986-03-13	1988-04-05	Vipont Laboratories, Inc.	Method for inhibiting bone resorption and collagenase release
EP0326627A1 (de) *	1988-02-01	1989-08-09	Vipont Pharmaceutical, Inc.	Methode zur Verhinderung der Knochenresorption und der Kollagenasefreisetzung

1995
- 1995-06-01 AT AT0093695A patent/AT407833B/de not_active IP Right Cessation
1996
- 1996-05-29 ZA ZA964387A patent/ZA964387B/xx unknown
- 1996-05-30 CA CA002222539A patent/CA2222539A1/en not_active Abandoned
- 1996-05-30 NZ NZ308024A patent/NZ308024A/xx unknown
- 1996-05-30 WO PCT/AT1996/000099 patent/WO1996038154A1/de not_active Ceased
- 1996-05-30 UA UA97126207A patent/UA42842C2/uk unknown
- 1996-05-30 DE DE19680394T patent/DE19680394D2/de not_active Ceased
- 1996-05-30 KR KR1019970708515A patent/KR19990022036A/ko not_active Ceased
- 1996-05-30 CZ CZ19973741A patent/CZ290489B6/cs not_active IP Right Cessation
- 1996-05-30 JP JP8536023A patent/JPH11505851A/ja not_active Ceased
- 1996-05-30 CN CNB961948922A patent/CN1167423C/zh not_active Expired - Fee Related
- 1996-05-30 EP EP96914004A patent/EP0831841A1/de not_active Ceased
- 1996-05-30 US US08/981,128 patent/US5981512A/en not_active Expired - Fee Related
- 1996-05-30 AU AU57549/96A patent/AU713853B2/en not_active Ceased
- 1996-05-30 SK SK1625-97A patent/SK282832B6/sk not_active IP Right Cessation

Also Published As

Publication number	Publication date
CA2222539A1 (en)	1996-12-05
JPH11505851A (ja)	1999-05-25
ZA964387B (en)	1996-12-09
AT407833B (de)	2001-06-25
ATA93695A (de)	2000-11-15
EP0831841A1 (de)	1998-04-01
WO1996038154A1 (de)	1996-12-05
DE19680394D2 (de)	2000-01-27
CZ374197A3 (cs)	1998-04-15
CN1188412A (zh)	1998-07-22
KR19990022036A (ko)	1999-03-25
US5981512A (en)	1999-11-09
CN1167423C (zh)	2004-09-22
AU713853B2 (en)	1999-12-09
CZ290489B6 (cs)	2002-08-14
SK162597A3 (en)	1998-05-06
UA42842C2 (uk)	2001-11-15
AU5754996A (en)	1996-12-18
NZ308024A (en)	2000-08-25

Legal Events

Date	Code	Title	Description
2010-02-08	MM4A	Patent lapsed due to non-payment of maintenance fees	Effective date: 20090530

Publication	Publication Date	Title
US5780455A (en)	1998-07-14	Intravenous alendronate formulations
EP0399051B1 (de)	1994-05-11	Polyvalentes entzündungshemmendes mittel
US3784704A (en)	1974-01-08	Compositions of 4-biphenyl acetic acid and method of use
JPH08512311A (ja)	1996-12-24	慢性疲労症候群治療用ヒ素医薬
AU713853B2 (en)	1999-12-09	Agent for the treatment of radiation injuries
US4877794A (en)	1989-10-31	2-Alkoxy-n-(1-azabicyclo(2.2.2)oct-3-yl) benzamide and thiobenzamide compositions and the use thereof to treat schizophrenia
Dinger et al.	1993	Arthrogryposis multiplex in a newborn of a myasthenic mother—case report and literature
JPH0825885B2 (ja)	1996-03-13	特発性血小板減少性紫斑病治療剤
Fawcett et al.	1983	Prophylactic topical acyclovir for frequent recurrent herpes simplex infection with and without erythema multiforme
JP2000501085A (ja)	2000-02-02	多発性硬化症を治療するためのペントキシフィリンと▲ｉ▼型インターフェロン類の併用
CA2221416A1 (en)	1996-12-12	Bisphosphonate therapy for bone loss associated with rheumatoid arthritis
JPH0475205B2 (de)	1992-11-30
JPH02184632A (ja)	1990-07-19	医薬組成物
Curwain et al.	1972	The effects of B2-adrenoceptor stimulants, salbutamol and terbutaline on gastric acid secretion and mucosal blood flow in conscious dogs with Heidenhain pouches
JPH05504130A (ja)	1993-07-01	腫瘍壊死因子拮抗剤
Husby et al.	1975	Comparative double-blind trial of intra-articular injections of two long-acting forms of betamethasone
EP0245954B1 (de)	1992-07-29	Verwendung von Etodolac zur Senkung des Blutgehalts an Harnsäure
EP0369776B1 (de)	1995-05-24	Verwendung einer Zusammensetzung, die organisch gebundenes Germanium enthaltet, zur Herstellung von Arzneimitteln zur Behandlung von AIDS
US4742076A (en)	1988-05-03	Etodolac for lowering rheumatoid factor
POLEC et al.	1971	Protective effect of ascorbic acid, isoascorbic acid and mannitol against tetracycline-induced nephrotoxicity
US20080146592A1 (en)	2008-06-19	Method of Treating Preeclampsia Employing Metolazone
Shaw et al.	1989	Skin rash after completion of therapy for leukemia in childhood
IT8921930A1 (it)	1991-04-05	Composti per il trattamento della malattia cerebrovascolare cronica, ottenuti per complessazione della diidroergocristina con una ciclodestrina, loro preparazione e loro utilizzazione.
JPS58216119A (ja)	1983-12-15	抗潰瘍剤
JPH07133223A (ja)	1995-05-23	３ーオキシゲルミルプロピオン酸化合物を主成分とする免疫疾患諸症状の発症予防及び治療剤